Hardy Diagnostics has partnered exclusively with Gradientech to distribute QuickMIC® — a rapid antimicrobial susceptibility testing system — in the United States and Canada. QuickMIC® offers essential results for sepsis patients, aiming to support timely antibiotic treatment decisions. This is identified as a critical need as sepsis impacts millions and results in high mortality rates annually. With sepsis requiring urgent action, often referred to as treatment within the 'golden hour,' QuickMIC® addresses this demand by providing faster lab results than traditional methods.
Currently undergoing clinical trials in the U.S., Hardy Diagnostics' rapid antimicrobial susceptibility testing system is already being utilized in various European hospitals. Through this collaboration, Hardy Diagnostics will leverage its extensive distribution network to introduce QuickMIC® across North America. This aligns well with Hardy’s experience and presence in the clinical microbiology field.
Image Credit: Hardy Diagnostics
What Makes This Trend Stand Out
- Rapid-diagnostic-technologies
- Emerging rapid-diagnostic technologies are crucial for reducing sepsis mortality by enabling quicker antibiotic treatment decisions.
- Clinical-trials-and-evidence-based-adoption
- The increasing emphasis on clinical trials and evidence-based adoption highlights the necessity for validated rapid testing systems in medical settings.
- Cross-continental-healthcare-solutions
- Partnerships that facilitate the introduction of innovative healthcare solutions across continents ensure a wider reach and greater impact on patient care.
Sectors Adopting This
- Medical-devices
- The medical devices industry is observing a shift towards rapid-diagnostic tools that promise expedited patient care for life-threatening conditions like sepsis.
- Clinical-microbiology
- The clinical microbiology field is adopting new testing systems that offer quicker results compared to traditional methods, improving treatment timelines.
- Pharmaceutical-distribution
- Pharmaceutical distributors are expanding their portfolios to include advanced diagnostic tools, facilitating their integration into North American healthcare systems.
